pwc glp 1 What is the future of GLP-1 trends: PwC has told US staff

Eli Lilly has committed nearly $50 billion to new U.S

This is essential for patient safety

Given the prominent role of IL-17driven inflammation in obese PsA patients, GLP-1RAs may also enhance the efficacy of biologic agents targeting these pathways

The Precision Peptide Genetic Test may provide context for peptide pathway predispositions, potentially supporting more targeted initial treatment selection

Here are the recent weight loss results for each medication: Wegovy (Novo Nordisk) had a 14.9% mean weight loss on the 2.4 mg weekly injection after 68 weeks during its Phase 3 STEP 1 study

One plausible explanation is that weight-loss use (reported more frequently by women) is also more likely to be paid out-of-pocket, whereas other medical motivations may align differently with coverage